The Broad Institute's microwell CARMEN chip. Photo: Michael James Butts

A new technology has been developed using CRISPR-based molecular diagnostics to run thousands of tests for diseases simultaneously, per a paper published in Nature today.

Why it matters: COVID-19 has painfully demonstrated the limits of conventional diagnostics methods for infectious disease. A new platform that would allow doctors to test a single sample for thousands of different pathogens could revolutionize disease response.

The new testing platform, called CARMEN and developed by scientists at the Broad Institute of MIT and Harvard, provides one possible answer to a question that often bedevils doctors: What are sick patients actually infected with?

  • Doctors often generally treat people who present with respiratory disease symptoms first, and then find out the cause later — or often, never.

How it works: The Broad Institute's new test uses rubber chips slightly larger than a smartphone, each with tens of thousands of "microwells" — compartments that hold two tiny droplets. One droplet contains viral genetic material from a sample, while the other contains virus-detection reagents.

  • When the detection droplet, which includes the CRISPR protein Cas13, finds the specific viral genetic sequence being targeted — like the novel coronavirus — it produces a detectable signal. The entire process can yield results in eight hours.

What they're saying: The new technology could help speed COVID-19 tests, but its bigger impact could be in enabling clinicians to rapidly test a patient sample for more than 150 different viruses.

  • "Imagine a world in which you go to the doctor and you actually find out what's making you sick," Cheri Ackerman, a postdoctoral student at the Broad Institute and lead author of the paper, said on a press call. "Instead of epidemiologists wondering what's circulating in a community, they'd be able to have accurate statistics of what's spreading and where."

Editor's note: This story has been corrected to reflect that Cheri Ackerman was quoted not Catherine Freije.

Go deeper

19 hours ago - Health

How to do smarter coronavirus testing

Illustration: Eniola Odetunde/Axios

With testing once again a huge vulnerability to America’s coronavirus response, public health officials are calling for a revamped strategy that features the use of more tests, even if they're imperfect.

Why it matters: The system is overwhelmed by the demand for tests, and yet prolific testing is key to identifying asymptomatic or pre-symptomatic coronavirus cases. Experts say the solution is smarter testing — which doesn't require perfect accuracy.

Aug 9, 2020 - Health

Ohio governor urges Americans not to lose faith in testing after false positive

Ohio Gov. Mike DeWine (R) said on CNN's "State of the Union" Sunday that Americans shouldn't think testing for the coronavirus is "not reliable or doesn't work," after he received a false positive result from an antigen test last week.

Why it matters: DeWine is one of six governors who have agreed to pool their resources, along with the Rockefeller Foundation, in order to acquire 3 million antigen tests amid severe delays and the lack of a national testing strategy.

Updated 4 hours ago - Health

World coronavirus updates

Data: The Center for Systems Science and Engineering at Johns Hopkins; Map: Axios Visuals

The number of COVID-19 cases surpassed 20 million worldwide on Monday evening, Johns Hopkins data shows.

The big picture: World Health Organization chief Tedros Adhanom Ghebreyesus told a virtual press conference as the world approached the milestone that 750,000 deaths were set to be recorded this week. "Behind these statistics is a great deal of pain and suffering. Every life lost matters," he said. "But I want to be clear: there are green shoots of hope and... it's never too late to turn the outbreak around."